Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruji Formula and Tumor Autoantibody Profiles in Breast Cancer
ChiCTR2200063988Phase 4Not yet recruiting
- Sponsor
- Foshan Hospital of TCM
- Start
- Jul 2022
- Countries
- 1
01
Overview
Phase 4, open-label trial of Ruji formula in breast cancer (2 arms), sponsored by Foshan Hospital of TCM. Primary endpoint: Tumor autoantibodies. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
Ruji formula
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200063988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063988.